Research programme: interleukin 1-beta converting enzyme inhibitors - Procter & Gamble

Drug Profile

Research programme: interleukin 1-beta converting enzyme inhibitors - Procter & Gamble

Alternative Names: Interleukin 1-beta converting enzyme inhibitors research programme - Procter & Gamble; PGE-3935199; PGE-527667

Latest Information Update: 15 Sep 2005

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Procter & Gamble
  • Class
  • Mechanism of Action Caspase 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Inflammation

Most Recent Events

  • 15 Sep 2005 Discontinued - Preclinical for Inflammation in USA (PO)
  • 09 Sep 2004 Preclinical trials in Inflammation in USA (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top